Identification and characterization of a Ross River virus variant that grows persistently in macrophages, shows altered disease kinetics in a mouse model, and exhibits resistance to type I interferon by Lidbury, Brett A. et al.
JOURNAL OF VIROLOGY, June 2011, p. 5651–5663 Vol. 85, No. 11
0022-538X/11/$12.00 doi:10.1128/JVI.01189-10
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Identification and Characterization of a Ross River Virus Variant That
Grows Persistently in Macrophages, Shows Altered Disease Kinetics in
a Mouse Model, and Exhibits Resistance to Type I Interferon£
Brett A. Lidbury,1† Nestor E. Rulli,1,2,3,4† Cristina M. Musso,1† Susan B. Cossetto,1 Ali Zaid,1,2
Andreas Suhrbier,5 Harald S. Rothenfluh,6 Michael S. Rolph,1,3 and Suresh Mahalingam1,2,3*
Virus and Inflammation Research Group, Faculty of Applied Science, University of Canberra, Canberra, ACT 2601, Australia1;
Virus and Inflammation Research Group, School of Biological Sciences, University of Wollongong, Wollongong, NSW 2522,
Australia2; Emerging Viruses and Inflammation Research Group, Institute for Glycomics, Griffith University, Gold Coast,
QLD 4222, Australia3; LISIN, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Buenos Aires, Argentina4;
Queensland Institute of Medical Research and Griffith University, Brisbane, Australia5; and Division of Immunology and
Genetics, John Curtin School of Medical Research, Australian National University, Canberra, ACT 0200, Australia6
Received 3 June 2010/Accepted 23 February 2011
Alphaviruses, such as chikungunya virus, o’nyong-nyong virus, and Ross River virus (RRV), cause outbreaks
of human rheumatic disease worldwide. RRV is a positive-sense single-stranded RNA virus endemic to
Australia and Papua New Guinea. In this study, we sought to establish an in vitro model of RRV evolution in
response to cellular antiviral defense mechanisms. RRV was able to establish persistent infection in activated
macrophages, and a small-plaque variant (RRVPERS) was isolated after several weeks of culture. Nucleotide
sequence analysis of RRVPERS found several nucleotide differences in the nonstructural protein (nsP) region
of the RRVPERS genome. A point mutation was also detected in the E2 gene. Compared to the parent virus
(RRV-T48), RRVPERS showed significantly enhanced resistance to beta interferon (IFN-b)-stimulated antiviral
activity. RRVPERS infection of RAW 264.7 macrophages induced lower levels of IFN-b expression and produc-
tion than infection with RRV-T48. RRVPERS was also able to inhibit type I IFN signaling. Mice infected with
RRVPERS exhibited significantly enhanced disease severity and mortality compared to mice infected with
RRV-T48. These results provide strong evidence that the cellular antiviral response can direct selective
pressure for viral sequence evolution that impacts on virus fitness and sensitivity to alpha/beta IFN (IFN-a/b).
Arthritogenic alphaviruses are distributed globally and are
maintained in nature by cycles of transmission between hema-
tophagous arthropods (for example, mosquitoes) and enzootic
vertebrate hosts (mammals, marsupials, or birds) (33, 53).
Nearly all symptomatic infections with these alphaviruses man-
ifest with joint symptoms (arthritis and arthralgia), with myal-
gia, rash, and lethargy also being common. Ross River virus
(RRV) is an Australian alphavirus associated with chronic
polyarthritis and causes up to 8,000 cases annually in Australia,
with the number of cases reported in new localities increasing
(42, 55). During the late 1970s and early 1980s, a number of
South Pacific island nations experienced a major outbreak of
RRV disease (RRVD) affecting more than 50,000 people (17).
More recently, a related virus, chikungunya virus (CHIKV),
caused similar rheumatic disease in one-third of the population
of Re´union Island in the Western Indian Ocean and an esti-
mated 1.39 million cases in India (22, 23, 37, 52). This outbreak
was also associated for the first time with some severe clinical
manifestation and mortality (37).
In RRV-infected patients, the disease is usually severe at
onset with a gradual resolution over 3 to 6 months (40). Al-
phavirus-induced rheumatic disease is thought to have a sub-
stantial immunopathological component. For example, in an-
imal models tissue damage results from the induction of
proinflammatory cytokines and chemokines and recruitment of
macrophages in response to infection (29, 43, 55). RRV infects
and replicates in human and mouse macrophages, and infec-
tion of the mouse macrophage cell line RAW 264.7 results in
the establishment of a persistent productive infection (11, 31,
36, 60), which has been regarded as a model of how RRV
persists in synovial tissues and produces arthritis/arthralgia (54,
55). Persistence of RRV occurs in RAW 264.7 cells despite the
ability of these cells to produce beta interferon (IFN-b) (30,
36), which is known to effectively control alphavirus replication
(44).
There is considerable evidence that RRV can persist and
establish chronic infection. For example, Soden et al. (50)
showed genetic evidence of RRV in synovial tissue of 2 pa-
tients from a cohort of 12, 5 weeks after initial symptoms of
RRV infection were reported. We have also obtained evidence
for chronic infection in a mouse model of RRV infection, with
RRV RNA being detected in the ankle joints of mice 3 months
after infection (N. Rulli and S. Mahalingam, unpublished
data). A number of cell culture models of RRV persistence
have also been described. Journeaux et al. (21) established
long-term infection (up to 35 days) of primary human synovial
cell cultures (which were found to contain “macrophage-like
cells”). Small-plaque variants developed in these cultures, sug-
gesting that RRV underwent mutation and adaptation to the
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culture conditions. We have previously described persistent
RRV infection in macrophages for periods up to 180 days (60).
We have also recently observed persistent infection in murine
and human osteoblast cultures, suggesting that these cells may
also be persistently infected in vivo (N. Rulli, R. Li, P. Smith,
A. Choo, C. Musso, Y. C. Su, B. Lidbury, and S. Mahalingam,
unpublished data). Long-term persistence of antigen from the
related alphavirus chikungunya virus has recently been found
in perivascular synovial macrophages in one chronically in-
fected patient 18 months after initial infection (19). With a
macaque model, Labadie et al. observed long-term chikungu-
nya virus infection in joints, muscles, lymphoid organs, and
liver, which may explain the long-lasting disease symptoms
observed in humans (26). In addition, the authors identified
macrophages as the main cellular reservoirs during the late
stages of chikungunya virus infection in vivo (26).
Here we describe the generation of a small-plaque mutant of
RRV (RRVPERS) derived from persistently infected RAW
264.7 macrophages that had been stimulated with lipopolysac-
charide (LPS) to induce an antiviral phenotype, including the
production of alpha/beta interferon (IFN-a/b) (30, 34).
RRVPERS displayed significantly increased resistance to IFN-
b-induced antiviral activity compared to the parental RRV-
T48 virus. RRVPERS also induced lower levels of type I IFN
than RRV-T48 and was able to inhibit type I IFN signaling.
RRVPERS infection of mice resulted in increased morbidity,
mortality, and disease kinetics. Sequencing of RRVPERS iden-
tified 12 substitutions in the E2 and nsP regions of the
RRVPERS genome. The study provides the evidence for an
arthrogenic alphavirus that specifically targets host IFN-a/b
responses, leading to increased pathogenicity. RRVPERS ap-
pears to have evolved specific strategies to counteract the IFN-
a/b-induced antiviral responses, and we speculate that a sim-
ilar evolution may occur in vivo.
MATERIALS AND METHODS
Ross River virus and macrophage cell line. Ross River virus (RRV) derived
from an infectious clone of strain T48 (originally designated RR64) (25) was
used to initially infect the mouse macrophage cell line RAW 264.7 (ATCC
TIB-71) cultured at 5.0 3 105 cells per well/ml in 24-well trays (Nunc, Roskilde,
Denmark). To produce infectious virus, pRR64 was linearized by SacI digestion
and transcribed in vitro from the cDNA using SP6 RNA polymerase, and the
infectious RNA was transfected into BHK-21 cells as previously described (25).
Viral stocks were propagated in Vero cells (ATCC CCL-81), as previously
described (28), and no virus stock exceeded two Vero cell passages prior to
experimental use. Viral titers were determined by plaque assay with Vero cells
(see details below).
RAW 264.7 cells were maintained in Eagle minimal essential medium
(EMEM) (Thermo-Trace, Melbourne, Australia) supplemented with 5% heat-
inactivated fetal calf serum (HI-FCS) (Thermo-Trace), 1% penicillin-streptomy-
cin, 1 to 1.5% sodium bicarbonate, and 2.0 mM L-glutamine (Thermo-Trace).
Following RRV infection, 5.0 ng/ml lipopolysaccharide (LPS) (Escherichia coli
serotype 0111:B4; Sigma) was added to the cultures, and this LPS concentration
was maintained over the entire experimental period.
RAW 264.7 cells were infected with RRV at a multiplicity of infection (MOI)
of 0.1 (in PBS plus 1% HI-FCS) for 1 h at 37°C. The virus inoculum was
removed, and 1.0 ml of fresh EMEM-FCS was added to each well, after which
the infected cultures were further incubated at 37°C (5.0% CO2, 95% humidity).
Culture supernatants were collected at several time points (days 1, 2, 5, 14, and
21) for RRV plaque assay. Fresh and warmed EMEM-FCS (500 ml per well) was
added to each well after sample collection.
Detection and purification of small-plaque RRV. The parent RRV-T48
plaques are visible on Vero cell monolayers by day 2 postinfection. To visualize
the small plaques by eye, an extra day of incubation was required at room
temperature. At day 14 postinfection (approximately 90% small plaques), small
plaques were purified by picking individual isolated small plaques from the
stained Vero cell monolayer. An isolated large plaque was also purified from the
same culture. Infected Vero monolayers were incubated under a semisolid agar
overlay (complete M199 [Thermo-TRACE] or DMEM supplemented with 2.0%
FCS, 0.02% DEAE-Dextran, 4.0% heat-inactivated newborn serum [Thermo-
TRACE], and 1.0% agar [Bacto Laboratories Pty. Ltd., Liverpool, Australia],
penicillin-streptomycin, L-glutamine, and sodium bicarbonate at the final con-
centrations described above), and at day 2 or 3 of incubation, 0.02% neutral red
in phosphate-buffered saline (PBS) (pH 7.4) supplemented with 2.0% penicillin-
streptomycin and 0.7% agar was added to the agar overlay and the plaque assays
were incubated for a further 1 to 2 h at 37°C. The agar plugs were carefully
removed, and individual plaques were picked by holding a pipette tip directly on
top of the plaque and gently pipetting 10 ml of complete EMEM-FCS five times
onto the plaque. After the final wash, the 10-ml sample was diluted in 1.0 ml of
complete EMEM-FCS and added to a fresh monolayer of confluent Vero cells in
a 25-cm3 flask (Corning, NY), and the culture was incubated at 37°C (5.0% CO2,
95% humidity). As soon as cytopathic effect was observed in the Vero cell
monolayer (2 to 3 days postinfection), the infectious supernatants were collected
and centrifuged to remove cell debris (400 3 g). Plaque assays were carried out
to confirm the small-plaque phenotype in fresh Vero cell cultures and to estimate
the virus concentration (log10 PFU/ml). This plaque purification procedure was
then repeated with isolated plaques found on the fresh Vero cell monolayers.
After the second round of purification, stocks of small- and large-plaque (parent)
virus were grown in fresh Vero cell cultures, as described above; these stocks
were used for all subsequent experiments and nucleotide sequence analyses. The
small-plaque RRV was designated RRVPERS. These studies are covered by a
license from the Australian Government’s Office of Gene Technology Regulator
(license number DNIR 389/2006).
RRV neutralization by polyclonal anti-RRV sera and anti-RRV-E2 monoclo-
nal antibodies. Murine anti-RRV polyclonal serum was added to Hanks balanced
salt solution (HBSS) (pH 7.2), Thermo-Trace, Melbourne, Australia) containing
2% (wt/vol) bovine serum albumin (BSA) (Sigma, Missouri) to a final dilution of
5.0 3 1021. Serial 10-fold dilutions of this polyclonal serum were then prepared.
An equal volume of HBSS-BSA containing 200 PFU of RRV-T48 or RRVPERS
was added to the diluted antibody. The antibody-virus preparations were incu-
bated at 37°C for 1 h, after which 100 ml was plated on confluent Vero cell
monolayers and incubated at 37°C (5% CO2, 95% humidity) for 48 h. The
monolayers were stained for plaque enumeration exactly as described above.
Reaction of RRVPERS or RRV-T48 with E2-specific monoclonal antibodies
(MAbs) was performed exactly as described above for polyclonal sera. MAbs
designated 10C9, 3C4, and E7 were generously provided by Ron Weir (Austra-
lian National University) and Roy Hall (University of Queensland) from a
previously described antibody panel (6).
RNA extraction and isolation of RRV genomic cDNA by Reverse transcriptase
(RT) PCR. Vero cells cultured in 25-cm3 flasks were infected with of RRVPERS
at an MOI of 0.1. As soon as cytopathic effect was observed (36 h postinfection),
culture medium was removed and cells were treated with 200 ml of acidified (pH
4.5) guanidinium isothiocyanate-phenol-sodium acetate (buffer), following the
protocol of Chomczynski and Sacchi (7). To isolate RRV-specific RNA from the
total RNA collected, reverse transcription (SuperScript preamplification system
for first-strand cDNA synthesis; Invitrogen, Carlsbad, CA) was performed using
either the RRV E2-specific antisense primer P2 or P5 (Table 1). Standard PCR
was then carried out with the same antisense primer as used for reverse tran-
scription and primer P1 (sense primer; see Table 1). Taq DNA polymerase,
deoxyribose nucleoside triphosphates (dNTPs), buffers, and magnesium chloride
(MgCl2) were supplied by Qiagen (Taq PCR core kit, catalog no. 201223)
(Hilden, Germany), and RRV E2 primers were synthesized by GeneWorks
(Adelaide, South Australia).
To specifically amplify the entire RRV E2 cDNA, the following cycling and
temperature protocol was used: denaturation at 94°C for 2 min (1 cycle), fol-
lowed by sequential denaturation, primer annealing, and strand elongation by
Taq cycles of 94°C (30 s) plus 60°C (40 s) plus 72°C (50 s) (35 cycles) and 72°C
(5 min) (1 cycle). For the primer sets used to amplify the entire RRV E2 gene
(primers P1 plus P2 or P1 plus P5) (Table 1), this protocol was performed with
equal efficiency.
Amplification of RRV nsP1 to nsP4 was achieved after the extraction of total
RNA from infected Vero cells, as described above, followed by RT using
oligo(dT) or gene-specific primer (Table 2) and the Superscript first-Strand
synthesis system (Invitrogen) to produce a single-stranded cDNA of the RRV
nsP sequence. The PCR amplification of nsP fragments utilized Proof Start DNA
polymerase (Qiagen), and reaction conditions were as recommended by the
manufacturers. Samples were amplified through 45 cycles of primer annealing for
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1 min at 58°C, elongation for 1 min at 72°C, and denaturation for 1 min at 94°C.
The primers used for reverse transcription and subsequent cDNA amplification
of viral nsP (Table 2) were designed on the basis of the complete genomic
sequence of RRV strain 48 (T48) (10). Prior to sequencing, the quality of the
PCR products were checked by agarose gel electrophoresis and ethidium bro-
mide staining.
Nucleotide sequencing of the RRVPERS E2 and nsP genes. ABI Prism BigDye
Terminator cycle sequencing chemistries (PE Applied Biosystems, California)
were used to generate the specific RRV E2 and RRV nsP sequences prior to gel
analysis, as described below. Thermal cycling protocols and conditions were run
according to the manufacturer’s recommendations.
RRV E2 gene sequencing. Template cDNA was included in the sequencing
reaction at 0.5 mg per reaction. The entire RRV-E2 cDNA sequence was ob-
tained using the primers listed in Table 1. Further confirmation of the single base
change found for RRVPERS was demonstrated by m13 sequencing of the
RRV-E2 cDNA after cloning into pUC-19. Briefly, the entire RRV-E2 cDNA
was cloned into the EcoRI site of pUC-19 at a 3:1 insert-to-vector ratio with T4
DNA ligase (Promega Corp.). To facilitate cloning, the ends of the RRV-E2
cDNA were modified during PCR amplification to incorporate EcoRI sites; this
was achieved by the addition of GCGCGAATTC to the 59 end of primers P1 and
P2 (Table 1) (45). Amplification and sequencing were repeated to confirm base
changes. After the above preparations, gel analysis of the RRV-E2 gene se-
quence was performed through the DNA Sequencing Analysis Facility at the
University of New South Wales, Sydney, Australia.
nsP gene sequencing. PCR products were cut from the 1% agarose gel and
purified using a minicolumn system (Millipore). PCR sense and antisense prim-
ers (Table 2) were used as sequencing primers to ensure full coverage of the
RRV nsP1 to nsP4 genes. Amplification and sequencing were repeated to con-
firm base changes. Thermal cycle sequencing reactions and gel analyses were
carried out at the Australian National University (ANU) Sequencing Core Fa-
cility.
Growth kinetics of RRV. Vero, HEp-2 (a human laryngeal epithelial cell line),
and RAW 264.7 cells were cultured in EMEM-FCS at 37°C (5.0% CO2, 95%
humidity). Cells were infected with RRV-T48 or RRVPERS at an MOI of 0.1.
Culture supernatants were collected at 12, 24, and 48 h postinfection, and viral
growth was assessed by plaque assay on Vero cell monolayers.
In a separate experiment, RAW 264.7 cells were pretreated with medium
containing anti-murine IFN-a and anti-murine IFN-b (104 U/ml; both from
R&D Systems) for 1 h at 37°C. The treated cells were then infected with
RRV-T48 or RRVPERS at an MOI of 0.1 for 1 h at 37°C. Cells were then washed,
and fresh medium containing 104 U/ml of anti-murine IFN-a and anti-murine
IFN-b antibodies was added to the cells. Supernatants were collected at 12, 24,
and 48 h postinfection, and viral growth was assessed by plaque assay on Vero
cell monolayers.
Determination of RRV infectivity by IFA. The percentage of infected cells was
determined by immunofluorescence assays (IFA) at 6, 12, and 24 h postinfection
as described previously (30). Briefly, confluent virus-infected and noninfected
control cells in glass chamber slides were fixed for 1 min with a 1:1 ratio of
TABLE 1. Primers used for RT-PCR isolation and nucleotide sequence analysis of the RRV E2 gene from
a small-plaque variant of RRV-T48
Primer Polarity Position (59)a Oligonucleotide sequence (59–39)b Product size (bp)
P1 1 8545 GAAACAGATCACGCCACCGC 1,289
P2 2 9834 CTGCGTTCGCCCTCGGTGCG
P3 1 8946 GTCCAATACAAGCACGACCC
P4 2 9454 TAGGAGAAGAGCGTCGGATG
P5 2 10035 GAATTGTGGCTGTGTGCTCGb 1,490 (with P1)
a Position of primer in complete RRV genome (refer to reference 10).
b Primers used for RT-PCR amplification of RRV E2. The E2 gene is 1,268 bp in length (position 8566 to 9834) and is situated between the E3 and 6K coding regions
of the RRV genome (10).
TABLE 2. Primers used for nucleotide sequence analysis of the RRV nsP1 to nsP4 genes from RRVPERS
Primer Polarity Position (59) Oligonucleotide sequence (59–39) Product size (bp)
P1 1 7 GGACGTGTGACATCACCGTTC 655
P2 2 662 GGAATACGTTGGGTATGCGCC
P3 1 603 GGATTCGACACCACCCCATTC 650
P4 2 1253 CTTGCTGAAAGCTTGGGCCAC
P5 1 1147 TACTGGTGGGGTTGAACCAAC 697
P6 2 1844 TCCTGAGTGCGTCATGATTGTC
P7 1 1744 CGCGTACCTGATCTTGTCTC 708
P8 2 2452 TGACAGGCAAATGCTTCGTCC
P9 1 2352 AGAGGACTGGATGTAACAGCC 630
P10 2 2982 ACACCTTTATCCACGGGTCTC
P11 1 2939 GCTGGTGTGGAAAACACTGTC 641
P12 2 3580 TGGTATCCGGGAAGCTTCTTC
P13 1 3361 GCGAAGTCGCCCGTAAGTTTG 776
P14 2 4137 CATTGACAACCGCCTCTTCGG
P15 1 4076 ACCCTCATACCGTGTGCGTAG 756
P16 2 4832 CGAATCGGCGTCCTCAACAG
P17 1 4795 GCATCAGAACGAAATGCCCTG 777
P18 2 5572 TCAACCGGCTCGCGCATTTTG
P19 1 5514 CTGAAGATCTGGAGGTACTCAC 827
P20 2 6341 TAGAGTGGGTAGCTCTCTCATC
P21 1 6242 CGCGGTCCCATCACCATTTC 677
P22 2 6919 ATTTCCCCGAACGCTGCCTC
P23 1 6840 TTGACGGCACTGATGCTGTTG 680
P24 2 7520 TTTAGGACCGCCGTAGAGGTG
P25 1 7311 CAAGATGAAGATCGTAGGCGTG 439
P26 2 7750 CTGTTTGGTGGTTAGTGCAGAG
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acetone-methanol, followed by overnight incubation at 4°C in PBS. The cells
were then incubated at 37°C for 2 h with mouse anti-RRV hyperimmune ascitic
fluid diluted (1023) in PBS containing 1% HI-FCS, followed by three washes
with sterile PBS. This was followed by incubation of the cells with fluorescein
isothiocyanate (FITC)-conjugated sheep anti-mouse IgG antibody (Silenius,
Melbourne, Australia) in PBS (1% HI-FCS) for 1 h at 37°C. Cells were then
washed three times with sterile PBS. Cells were counted with a Leica fluores-
cence microscope.
IFN-b treatment of RAW 264.7 cells. RAW 264.7 cells were cultured in
EMEM-FCS containing 10, 50, or 100 IU/ml of recombinant mouse IFN-b
(catalog no. PMC4024; Invitrogen, Australia) for 24 h prior to infection with 0.1
MOI of parent RRV-T48 or RRVPERS. Supernatants were collected 12 h postin-
fection (p.i.) and titrated by plaque assay on Vero cell monolayers for determi-
nation of virus titers.
Plasmids and DNA transfection for luciferase assay. The luciferase reporter
plasmid constructs pIFN-b (2125/172) Lucter and pISRE (9-27) Lucter were
used in experiments involving transfection of RAW 264.7 cells and Vero cells,
respectively. Plasmid DNA was transfected using the GeneJammer transfection
reagent, following the manufacturer’s protocol (Stratagene). For RAW 264.7 cell
experiments, cells were transfected with 2 mg of pIFN-b (2125/172) Lucter
together with an equal amount of pCMV-bGal plasmid (Promega) as an internal
control. Cells were cultured for a further 24 h and then were infected with 0.1
MOI of RRV-T48 or RRVPERS. Cells were harvested at 12 h postinfection and
processed for measurement of luciferase activity (luciferase reporter assay kit;
Promega) and b-galactosidase activity (b-galactosidase reporter assay kit; Pro-
mega) according to the manufacturer’s instructions. Luciferase activity was read
on an Ascent Luminoskan luminometer (Pathtech), and b-galactosidase activity
was measured on a UV-visible microplate reader at 495 nm (Bio-Rad). For Vero
cell experiments, cells were transfected with 2 mg of pISRE (9-27) Lucter and 2
mg pCMV-bGal (Promega). Cells were then infected with RRV-T48 or
RRVPERS at an MOI of 5. Twelve hours later, IFN-b (100 IU/ml) was added to
cell culture and luciferase expression was measured at 6 h following incubation.
Quantitative real-time PCR. Total RNA was isolated from RAW 264.7 cells
infected with RRV-T48 or RRVPERS at an MOI of 0.1 using TRIzol (Invitrogen
Life Technologies). Real-time PCR for IFN-b was carried out on the Rotor-
Gene RG-3000 thermal cycler (Corbett-Research, Australia), using Quantitect
primer assay kits (Qiagen, Germany) based on quantification of the SYBR green
I fluorescent dye. Data were normalized to data for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH).
For viral quantitation by real-time PCR, the method of Shabman et al. was
used (48). Briefly, RNA was purified from infected culture medium using a
MagMAX viral RNA isolation kit (catalog no. AM1939; Ambion). Virion RNA
was reverse transcribed using leukemia virus reverse transcriptase (invitrogen),
and the cDNA was used for quantitative real-time PCR. TaqMan primers/probes
specific for the NSP3 region of RRV were used as described previously (48). A
DNA standard curve for the RRV genome was generated to ensure optimal
primer-probe efficiency and assign relative genome numbers for sample compar-
ison.
Semiquantitative RT-PCR analysis of the RRV E2 gene. Total RNA was
extracted from RAW 264.7 cells infected with RRV-T48 or RRVPERS at an MOI
of 0.1 using TRIzol (Invitrogen Life Technologies). Primer and probe sequences
for RRV E2 and hypoxanthine phosphoribosyltransferase (HPRT) have been
described (34, 60). The cycle numbers used for amplification of each gene
product are in the linear phase of amplification: E2, 25 cycles; hypoxanthine
phosphoribosyltransferase (HPRT), 23 cycles. The amplified DNA was analyzed
by gel electrophoresis and Southern blotting and detected using the ECL detec-
tion system as recommended by the manufacturer (Amersham). PCR amplifi-
cation with the HPRT reference gene was performed to assess variations in
cDNA or total RNA loading between samples. Relative transcript levels were
quantified in arbitrary units using the ImageJ software program (image process-
ing and analysis in Java; http://rsb.info.nih.gov/ij/).
IFN-b ELISA. The concentration of IFN-b in samples was determined by
enzyme-linked immunosorbent assay (ELISA) (Biomedical Laboratories) ac-
cording to the manufacturer’s instructions.
Western blot analysis. Total protein was obtained from RAW 264.7 cells
stimulated with 50 IU/ml IFN-b 24 h prior to RRV infection (MOI 5 0.1), and
cell lysates were analyzed by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and Western blotting performed using a polyclonal antibody
against the RRV E2 glycoprotein (kindly provided by L. Hueston, Westmead
Hospital, Sydney, Australia). Fluorescence was detected by ECL Plus immuno-
fluorescence (Amersham). In a separate experiment, HEp-2 cells were infected
for 12 hwith parent RRV-T48 or RRVPERS at an MOI of 5, followed by IFN-b
treatment (100 IU/ml) for 30 min or no treatment. Proteins were analyzed from
whole-cell protein extracts by immunoblotting as previously described (49). The
following primary antibodies recognizing nonphosphorylated and phosphory-
lated (P) forms of STAT-1 and STAT-2, a-actin (loading control), and secondary
antibody were purchased from the indicated manufacturers: anti-STAT-1 (sc-
345), anti-P-STAT-1 (sc-135648), anti-STAT-2 (sc-476), anti-P-STAT-2 (sc-
21689), and anti-a-actin (from Santa Cruz Biotechnology) and peroxidase-con-
jugated goat anti-rabbit antibody (from Jackson Immunoresearch).
Outbred mouse mortality and morbidity studies. Mice were obtained from the
Animal Resources Centre, Canning Vale, Western Australia. Fourteen-day-old
Swiss outbred mice were inoculated intraperitoneally (i.p.) with 100 ml PBS–1%
FCS containing various doses (from 104 to 106 PFU) of plaque-purified parent
RRV (RRV-T48) or purified RRVPERS. Plaque assays on T48 and RRVPERS
stocks used in mouse experiments were performed in parallel using the same
batch of Vero cells. Both parent RRV and RRVPERS showed stock titers of.108
PFU/ml. In addition, to reflect equal particle doses, specific infectivity of the
RNA of each virus was determined by the overlay of agarose on transfected
BHK-21 cells and the enumeration of plaques from each virus. The specific
infectivities of RRV-T48 and RRVPERS were found to be similar (for RRV-T48,
1.8 3 105 PFU per mg of RNA; for RRVPERS, 1.9 3 105 PFU per mg of RNA).
Experiments were performed to compare RRVPERS and parent RRV titers in
mouse serum at 24 h p.i. with 104 PFU RRV. Control mice inoculated i.p. with
PBS alone showed no mortality or disease symptoms over the experimental
period. All experiments were approved by the Animal Ethics Committee of the
University of Canberra and Australian National University. In a separate exper-
iment, 5-week-old Swiss outbred mice were inoculated in the right hind-leg
footpad with 104 PFU RRVPERS or RRV-T48. At 1 day postinfection, mice were
sacrificed and popliteal lymph nodes were collected and homogenized for IFN-b
ELISA analysis.
Outbred mouse RRVD studies. The experimental approach used for murine
RRV infection and monitoring of clinical disease was as described previously by
Lidbury et al. (28, 29). Eighteen-day-old mice were inoculated subcutaneously in
the pectoral area with 104 PFU of RRV diluted in PBS (pH 7.2) in a 20-ml
volume. Mock-inoculated animals were injected with the diluent alone. Mice
were scored for disease symptoms every 24 h. Signs of disease were determined
by assessing grip strength and altered gait. Mice were scored as follows: 0, no
disease; 1, ruffled fur; 2, very mild hind limb weakness; 3, mild hind limb
weakness; 4, moderate hind limb weakness; 5, severe hind limb weakness/drag-
ging; 6, complete loss of hind limb function; 7, moribund; 8, dead. The experi-
ments were approved by the Animal Ethics Committee of the University of
Wollongong.
Statistical analysis. The significance of differences between experimental
groups was analyzed by one-way analysis of variance (ANOVA) followed by
Bonferroni’s test. Values were reported as the means 6 standard errors (SEM).
For disease scores, data were analyzed by using the Mann-Whitney test. For
survival studies, survival curves were analyzed by using the log rank test. Statis-
tical analyses were performed using the GraphPad 63721 Prism software pro-
gram, version 4.0b (GraphPad Software Inc.). Differences in means were con-
sidered significant at P values of ,0.05.
RESULTS
Kinetics of small-plaque RRV growth. To study the interplay
between virus and host antiviral pathways, we established per-
sistent RRV infection in macrophages that had been treated
with LPS to stimulate antiviral activity. In LPS-treated RAW
264.7 cell cultures, small plaque mutants of RRV first emerged
at day 5 postinfection and coexisted with large (parent RRV)
plaques. By day 14 postinfection, 90% of plaques visible on
Vero cell monolayers were of the small phenotype (Table 3).
In cultures treated with polymyxin B sulfate (to remove LPS)
at the same time as RRV infection, the appearance of small
plaques was delayed until day 14 postinfection (data not
shown). RRVPERS maintained a small-plaque phenotype after
several rounds of plaque purification and growth in fresh Vero
cell cultures (Fig. 1A).
To determine whether there were differences in the growth
of RRV-T48 and RRVPERS, kinetics of virus growth were
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compared in Vero, HEp-2, and RAW 264.7 cells. There were
no significant differences in growth kinetics observed in Vero
cells (Fig. 1B) (which do not make IFN-a/b) and in HEp-2
cells (Fig. 1C). In contrast, in RAW 264.7 cells, growth kinetics
for RRV-T48 and RRVPERS differed, with RRVPERS produc-
ing .1 log10 more virus at 24 and 48 h postinfection (Fig. 1D).
Importantly, growth kinetics for RRV-T48 and RRVPERS were
not significantly different in RAW 264.7 cells pretreated with
anti-murine IFN-a and anti-murine IFN-b antibodies (Fig.
1E). These findings suggest that the enhanced growth of
RRVPERS in RAW 264.7 cells involves modulation of the IFN-
a/b response.
Characterization of RRVPERS using monoclonal antibodies.
Using polyclonal anti-RRV antibodies, plaque inhibition as-
says (PIA) showed a 50% neutralization endpoint for small-
plaque RRV identical to that for the parent RRV-T48 virus
(1.9 3 1025 versus 1.5 3 1025), confirming the identity of the
small-plaque virus as RRV (Table 4).
TABLE 3. Mean RRV titers in RAW 264.7 murine macrophages
over 21 days p.i.a
Day p.i. Mean RRV titer(log10 PFU/ml) 6 SEM
1...............................................................4.77 6 0.02 (0 small plaques)
2...............................................................5.27 6 0.16 (0 small plaques)
5...............................................................5.34 6 0.11 (27, 5.8, 8.5b)
14.............................................................5.93 6 0.14 (89, 93, 91b)
21............................................................. 4.01 (80b,c)
a Cells were infected at an MOI of 0.1 on day 0 (n 5 3) and cultured with 5
ng/ml LPS. Virus used in this experiment was derived from the RRV-T48 genetic
clone (RR64).
b Proportion(s) (%) of small RRV plaques observed on Vero cell monolayers
after RAW 264.7 macrophage infection (n 5 3 except where otherwise noted)
over a 21-day period. Parent virus (RRV-T48) presents as a “large” plaque on
Vero cell monolayers (Fig. 1). At days 1 and 2 post-RRV-T48 infection, only
large plaques were observed.
c n 5 1.
FIG. 1. Differential plaque morphology and growth kinetics of RRVPERS compared to those of RRV-T48. (A) Plaque morphology on Vero cell
monolayers for parent Ross River virus strain T48 (RRV-T48) and RRVPERS. Both RRV-T48 and RRVPERS plaques were purified from the
supernatants of RRV-T48-infected RAW 264.7 cultures at day 14 postinfection, and new viral stocks were regrown in fresh Vero cell cultures, after
which plaque morphology was confirmed by plaque assay. (B and D) Growth kinetics of RRV-T48 and RRVPERS in Vero (B), HEp-2 (C), or RAW
264.7 (D) cells infected at an MOI of 0.1. (E) RAW 264.7 cells were pretreated with 104 U/ml of anti-murine IFN-a and anti-murine IFN-b
antibodies (R&D Systems) for 1 h at 37°C. The cells were then infected with 0.1 MOI RRV-T48 or RRVPERS for 1 h at 37°C. The virus inoculum
was discarded, and cells were rinsed with medium. Fresh medium containing 104 U/ml of anti-murine IFN-a and anti-murine IFN-b antibodies
was added to the monolayer for an additional 48 h at 37°C. Culture supernatants were collected at various time points post-RRV infection, and
viral growth was assessed by plaque assay on Vero cell monolayers. The assay limit of detection is 2.0 log10 PFU/ml. Significant differences in virus
titers (P , 0.05) are marked with an asterisk.
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PIA analysis using three monoclonal antibodies (MAbs) spe-
cific to the viral E2 protein revealed differences in neutraliza-
tion. For two of the three MAbs tested (E7 and 3C4), 50%
plaque neutralization antibody titers were significantly lower
for RRVPERS than for the parent RRV-T48 virus (Table 4).
The relative resistance of RRVPERS to neutralization by MAbs
E7 and 3C4 suggested an alteration in the RRV-E2 sequence
in the small-plaque variant.
Nucleotide sequence of RRVPERS. The E2 gene in RRVPERS
and RRV-T48 E2 were sequenced using RRV E2-specific
primers (Table 1) that covered the entire 1,266-bp sequence.
E2 PCR products were also cloned into the EcoRI site of
pUC-19, and forward and reverse m13 nucleotide sequencing
was performed. Analysis of the E2 sequences revealed a single
nucleotide change at position 347 (59339) of the RRV E2 gene
sequence (RRV-T48, [GAG]; small-plaque RRV, [GUG]).
This genetic alteration resulted in a nonconservative change
from the acidic (negatively charged) glutamic acid residue at
amino acid position 116 of the parent virus E2 protein to a
nonpolar hydrophobic valine residue in RRVPERS (Table 5).
Sequence analysis of the untranscribed regions (UTRs) and
other genes encoding RRV structural proteins outside the E2
gene (e.g., 6K, E1, and E3) did not show any differences be-
tween RRVPERS and RRV-T48 (data not shown).
The complete nsP region of RRVPERS was sequenced and
compared with sequence of the parent strain virus, RRV-T48
(NCBI accession number DQ226993). Sequence analysis was
started from 21 nucleotides 59 of the polyprotein start codon
(AUG) (position 59 in full-length RRV sequence) and finished
at the nsP4 stop codon (UAA; position 7523). The genomic
organization was the same for RRVPERS and RRV-T48. Four
silent mutations and 11 mutations resulting in single amino
acid substitutions were identified in RRVPERS nsP1 to nsP4
(Table 5). No base deletion or nonsense mutations were found.
RRV-T48 and RRVPERS nsPs thus showed an average
amino acid identity of 99%. Eighty-three percent (83%) of the
amino acid substitutions are within the nsP1 and nsP2 regions.
The majority of amino acid changes were nonconservative.
Interestingly, a nonconservative change of arginine (basic) to
proline (hydrophobic) was present near the center of the nsP1
protein (Pro-303), a region that is highly conserved among
alphaviruses (10).
RRVPERS induces less IFN-b mRNA expression and protein
production. To determine whether RRV-T48 and RRVPERS
differentially affect IFN-b production, the levels of IFN-b
mRNA were measured in RAW 264.7 cells infected with each
virus. The increase in IFN-b mRNA expression in response to
RRVPERS infection was significantly less than that in cells
infected with RRV-T48 (Fig. 2A). This reduction in IFN-b
mRNA expression occurred despite the fact that RRVPERS-
infected cells contained about 4-fold more genomic RNA than
RRV-T48-infected cells as determined by semiquantitative
RT-PCR analysis of RRV-E2 gene expression (Fig. 2B and C).
Using a reporter plasmid encoding luciferase under the control
of the IFN-b promoter, RRVPERS-infected cells also showed a
2-fold reduction in luciferase activity compared to that of
RRV-T48-infected cells (Fig. 2D). ELISA analysis confirmed
these observations, with 2.5-fold more IFN-b protein in cells
infected with RRV-T48 than in cells infected with RRVPERS
(Fig. 2E). These observations clearly show that infection of
RAW 264.7 cells with RRVPERS induced less IFN-b than in-
fection with RRV-T48 and suggest that the increased replica-
tion of RRVPERS in RAW 264.7 cells (Fig. 1D) may due to
lower levels of IFN-a/b induction.
In addition, we sought to exclude the possibility that reduced
IFN-a/b production in cells infected with RRVPERS was due to
differences in the number of cells infected early during infec-
tion. The percentages of cells infected with each virus at 6, 12,
and 24 h postinfection were measured. At 6 h postinfection,
the percentages of cells infected with each virus were found to
be similar (Fig. 2F). However, at 12 and 24 h postinfection, a
higher percentage of RRV-positive cells was detected in cul-
tures infected with RRVPERS than in cultures infected with
RRV-T48 (Fig. 2F). This result suggests that the differences in
the induction of IFN-a/b between RRV-T48 and RRVPERS
were not due to differences in the percentage of cells infected
at early time points after infection.
TABLE 5. Predicted amino acid differences in the nsP1 to nsP4
and E2 proteins of persistent RRVPERS compared to sequence
of the parent, RRV-T48a
Protein
Amino
acid
position
Amino acid (nucleotides) Conservation
(1/2)
Nucleotide
positionRRV-T48 RRVPERS
nsP1 143 R (AGA) T (ACA) 2 450
147 A (GCT) S (TCT) 2 461
154 X (NGG) A (GCG) 1/2 483
303 R (GCC) P (CCC) 2 929
499 K (AAG) N (AAT) 2 1519
nsP2 239 L (TTG) F (TTT) 1 2341
240 N (AAC) D (GAC) 2 2342
306 Y (TAC) H (CAC) 2 2540
634 H (CAT) Q (CAA) 2 3526
nsP3 337 S (AGC) I (ATC) 2 5028
nsP4 563 K (AAG) N (AAC) 2 7321
E2 116 E (GAG) V (GTG) 2 8913
a Based on nucleotide sequence analysis of the nsP1 to -4 region and E2, 6K,
and E1 (structural) regions of the RRV genome. (Silent mutations are not
included). Amino acid residues are numbered from the N terminus of each nsP
and E2 protein. The single-letter amino acid code is used. Conservative amino
acid differences are indicated by “1.” Amino acids that could not be deduced
due to nucleotide ambiguity (N) are shown as an X. Nucleotides are numbered
from the 59 terminus of the RRV Sp sequence. The GenBank accession number
for RRV E2 cDNA is M20162.
TABLE 4. Antibody-mediated inhibition of RRV plaque formation
on Vero cell monolayers by anti-RRV polyclonal sera or
RRV E2 protein-specific monoclonal antibodiesa
Anti-RRV antibody
Highest antibody dilution to achieve
50% RRV plaque inhibition
RRV-T48 RRVPERS
Polyclonal anti-RRVb 1.5 3 1025 1.9 3 1025
MAb E7c 7.5 3 1025 ,1021
MAb 10C9c 1.2 3 1024 3.5 3 1024
MAb 3C4c 1.2 3 1026 ,1021
a All antibodies were titrated by 1/10 serial dilution from 1/50 3 106 to
1/5 3 106 prior to mixing with 200 PFU of purified RRV.
b Polyclonal antibody to RRV raised in ascitic fluid to PEG-purified RRV-T48.
c Specific for the E2 protein of RRV.
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RRVPERS exhibits higher resistance to IFN-b-induced anti-
viral activity. We next investigated the effects of IFN-b treat-
ment on the replication of RRVPERS and RRV-T48 in RAW
264.7 cells. RAW 264.7 cells were treated with 10, 50m or 100
IU IFN-b and infected 24 h later with RRVPERS or RRV-T48.
The amount of virus in the cultures was determined by plaque
assay, real-time PCR, and Western blotting. RRVPERS showed
increased resistance to IFN-b-mediated antiviral activity, with
RRVPERS-infected cells generating a substantially higher viral
load than cells infected with the parent RRV-T48 virus (Fig.
3A to D). Cells were also collected for Western blotting to
analyze RRV E2 glycoprotein levels. Qualitative analysis re-
veal that at 24 h postinfection, RRV E2 levels were higher in
RRVPERS-infected cells than in those infected with RRV-T48
(Fig. 3E). These results indicate that RRVPERS has increased
resistance to the antiviral activity of IFN-b.
Infection by RRVPERS shows inhibitory effects on type I IFN
signaling. To determine whether the resistance of RRVPERS to
IFN-b treatment is mediated by the inhibition of type I IFN
signaling, a plasmid encoding the luciferase reporter gene un-
der the control of type I IFN (ISRE)-responsive element was
used. These studies were carried out with Vero cells, which are
able to respond to IFN-a/b but do not produce these factors
themselves. Induction of luciferase can thus be attributed ex-
clusively to exogenously added IFN-b. Vero cells were trans-
fected with the pISRE-luc plasmid, followed by infection with
RRV-T48 or RRVPERS at an MOI of 5. IFN-b (100 IU/ml)
was added 12 h later, and luciferase expression was measured
6 h later. Luciferase expression from the ISRE promoter in
response to treatment with IFN-b was lower in cells infected
with RRVPERS than in those infected with RRV-T48 (Fig. 4A),
suggesting that RRVPERS is able to interfere with the IFN-a/b
FIG. 2. RRVPERS infection of RAW 264.7 cells triggers lower IFN-b expression and production. (A) Quantitative real-time PCR analysis of
transcript for IFN-b mRNA in RAW 264.7 cells 12 h after infection at an MOI of 0.1 with RRV-T48 or RRVPERS. Data represent the mean fold
change in mRNA levels from those for uninfected controls. GAPDH was used as a reference gene. Statistical analysis of relative expression results
was performed using the REST software program. Significant differences in expression (P , 0.05) are marked with an asterisk. (B and C)
Semiquantitative RT-PCR analysis of transcript for RRV E2 mRNA in RAW 264.7 cells 12 h after infection at an MOI of 0.1 with RRV-T48 or
RRVPERS. HPRT was used as a reference gene. Relative transcript levels were quantified in arbitrary units using the ImageJ software program
(Image Processing and Analysis in Java; http://rsb.info.nih.gov/ij/). (D) Luciferase reporter gene activity at 12 h after infection of RAW 264.7 cells
at an MOI of 0.1 with RRV-T48 or RRVPERS. RAW264.7 cells were transiently transfected with the pIFN-b (2125/172) Lucter reporter plasmid.
Twenty-four hours later, cells were inoculated at an MOI of 0.1 with RRV-T48 or RRVPERS, followed by cell lysis at 12 h postinfection. Luciferase
activity was normalized to b-galactosidase reporter expression. Significant differences in expression (P , 0.05) are marked with an asterisk.
(E) ELISA analysis of IFN-b protein production in RAW 264.7 cells 12 h after infection with 0.1 MOI of RRV-T48 or RRVPERS. Significant
differences in protein levels (P , 0.05) are marked with an asterisk. (F) Percentage of infected cells at 6, 12, and 24 h postinfection with 0.1 MOI
RRV-T48 or RRVPERS. Infected cells were detected using mouse anti-RRV hyperimmune ascitic fluid and fluorescein isothiocyanate (FITC)-
conjugated sheep anti-mouse IgG antibody. Infected cells were counted using a Leica fluorescence microscope. Significant differences (P , 0.05)
in cell numbers are indicated with an asterisk.
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receptor signaling pathway to a greater extent than wild-type
virus.
To further analyze IFN-a/b receptor signaling, we deter-
mined the levels of STAT-1 and STAT-2 phosphorylation in
HEp-2 cells infected with RRV-T48 or RRVPERS at an MOI
of 5 for 12 h followed by IFN-b (100 IU/ml) treatment for 30
min. Treatment with IFN-b resulted in high levels of
STAT-1 phosphorylation, but this was markedly reduced in
cells infected with RRVPERS from that in cells infected with
RRV-T48 (Fig. 4B and C). There were no detectable dif-
ferences in phosphorylated STAT-2, total STAT-1, total
STAT-2, and a-actin in cells infected with either of the
viruses (Fig. 4B and C). Similar results were obtained when
the same experiment was performed with Vero cells (data
not shown). Uninfected cells treated with IFN-b showed
levels of phosphorylated STAT-1 and STAT-2 comparable
to those for cells infected with RRV-T48 and treated with
IFN-b (Fig. 4C). These results suggest that RRVPERS and
not RRV-T48 can interfere with the IFN-a/b receptor sig-
naling pathway at the level of, or upstream of, STAT-1
phosphorylation. The observation that the inhibition of
STAT-1 phosphorylation was not associated with detectable
changes in STAT-2 phosphorylation, total STAT-1, total
STAT-2, and a-actin levels suggests that shutdown of host
protein synthesis was not responsible for this inhibition.
Infection of outbred mice with RRVPERS results in enhanced
mortality associated with high virus titers and reduced IFN-b.
To determine whether the altered in vitro phenotype of
RRVPERS resulted in increased pathogenicity in vivo, we un-
dertook infection studies in Swiss outbred mice, which have
been used extensively in RRV pathogenesis studies (58, 59).
Following infection of Swiss mice with a dose range of 104 to
106 PFU RRV (i.p.), markedly enhanced mortality was ob-
served for mice infected with RRVPERS compared to that for
those infected with RRV-T48 (Fig. 5A, B, and C). Serum RRV
titers were 1.5 log10 higher for RRVPERS-infected mice than
for RRV-T48-infected animals (P , 0.05) (Fig. 5D), suggest-
ing that the increased mortality in mice infected with
RRVPERS was related to enhanced viral replication.
To determine whether RRVPERS induces less IFN-b in vivo,
lymph nodes from 5-week-old Swiss outbred mice at 1 day
following infection with RRV-T48 or RRVPERS were homog-
enized and analyzed for the presence of IFN-b by ELISA.
Nearly 50% less IFN-b was detected in the lymph nodes of
mice infected with RRVPERS than in mice infected with the
RRV-T48 (Fig. 5E).
FIG. 3. RRVPERS exhibits enhanced resistance to antiviral stimuli. Growth of RRV-T48 and RRVPERS in RAW 264.7 cultures stimulated with
10 IU/ml (A), 50 IU/ml (B), or 100 IU/ml (C) IFN-b 24 h prior to RRV infection (MOI 5 0.1). Culture supernatants were collected at 12, 24, and
48 h post-RRV infection, and viral growth was assessed by plaque assay on Vero cell monolayers. The assay limit of detection is 2.0 log10 PFU/ml.
Significant differences in virus titers (P , 0.05) are marked with an asterisk. (D) Quantitation of the RRV genome by real-time PCR. RAW 264.7
cells were stimulated with 50 IU/ml IFN-b 24 h prior to RRV infection (MOI5 0.1). RNA was extracted at 24 h postinfection for the measurement
of RRV genome copy numbers. Significant differences in viral genome copy numbers (P , 0.05) are indicated with an asterisk. (E) Total protein
was obtained from RAW 264.7 cells stimulated with 50 IU/ml IFN-b 24 h prior to RRV infection (MOI 5 0.1). Cell lysates were collected at 24 h
postinfection for Western blot analysis using a polyclonal antibody against the RRV E2 glycoprotein. Detection of host cell protein expression by
anti-a-actin was used to demonstrate equal loading of protein.
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Infection of Swiss outbred mice with RRVPERS results in
enhanced severity of hind limb disease and myositis compared
to results with parent virus. We recently demonstrated that
Swiss outbred mice infected with RRV developed severe dis-
ease characterized by loss of hind limb gripping ability and
altered gait. These disease signs correlated with inflammation
of joint and skeletal muscle tissue (29, 38). Since RRVPERS has
enhanced virulence in vivo (Fig. 5), we examined its ability to
induce arthritis and myositis in Swiss outbred mice. Eighteen-
day-old mice were infected with 104 PFU RRVPERS or RRV-
T48, and mice were monitored for the development of disease
signs. Infection of mice with RRVPERS resulted in more-severe
disease than infection with RRV-T48 (Fig. 6A). Mice infected
with RRVPERS reached a level of disease requiring euthanasia
by day 10 postinfection.
To compare muscle tissue inflammation and pathology in
mice infected with RRVPERS and RRV-T48, histological anal-
ysis of skeletal muscle was performed. In RRVPERS-infected
mice, severe inflammation and tissue damage were observed in
muscle tissue at 5 days postinfection (Fig. 6B, panels c and f).
Inflammatory infiltrates were also observed in quadriceps skel-
etal muscle of RRV-T48-infected mice, but the level of inflam-
mation was not as severe and tissue damage was not apparent
at this time point (Fig. 6B, panels b and e).
DISCUSSION
In the present study, we characterized an RRV variant
(RRVPERS) that had been selected during persistent infection of
a mouse macrophage cell line under antiviral conditions.
RRVPERS formed small plaques and possessed mutations in the
structural and nsP regions. RRVPERS induced lower levels of type
I IFN and showed enhanced resistance to antiviral stimuli asso-
ciated with inhibition of IFN-a/b signaling. In association with
these changes, RRVPERS was highly pathogenic, with increased
disease severity and mortality following infection of mice.
Significant insights into the selection of an IFN-resistant
viral phenotype have come through the study of human hepa-
titis C virus (HCV), which successfully persists in some patients
(and cell cultures) for very long periods. The treatment of
HCV patients with IFN is often stymied by the eventual de-
velopment of IFN resistance by the virus. It has been suggested
that exogenous IFN treatment could lead to selective pressure
on the virus and the development of mutant strains able to
resist IFN-mediated host defense (16, 27, 56). Sumpter et al.
(56) found that persistent growth of HCV in cell culture was
associated with genetic variation of viral NS5A, NS3, and
NS4A, which endowed the virus with the ability to disrupt IFN
regulatory factor 1 (IRF-1) and IRF-3 signaling following IFN
FIG. 4. Type I IFN signaling is inhibited in cells infected with RRVPERS. (A) These studies were performed with Vero cells, which do not
produce IFN but are able to respond to IFN. Vero cells were transfected with the pISRE (9-27) Lucter plasmid and then infected with
RRV-T48 or RRVPERS (5 MOI). IFN-b (100 IU/ml) was added 12 h later, and luciferase expression was measured following incubation for
6 h. Luciferase activity was normalized to b-galactosidase reporter expression. Significant differences in expression (P , 0.05) are marked
with an asterisk. (B and C) Western blot analysis of STAT-1 and STAT-2 expression and phosphorylation in HEp2 cells infected with
RRV-T48 or RRVPERS (5 MOI) for 12 h, followed by IFN-b (100 IU/ml) treatment for 30 min or no treatment. The cell lysates were
examined by Western blotting with antibodies to STAT-1, pY-STAT-1, STAT-2, or pY-STAT-2. The control included the detection of host
cell protein expression by anti-a-actin antibody.
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stimulation. HCV proteins have been linked to the attenuation
of signaling via the IFN-a/b receptor (18), and HCV variant
E2 and NS5A proteins have been demonstrated to bind PKR
and interfere with IRF-1 stimulation (41, 57). The ability of
HCV to modulate the activity of type 1 IFN may contribute to
its ability to persist in the host. In the present study, we ob-
served that small-plaque variants also arose in unstimulated
RAW 264.7 cells but at a much lower rate than in cultures
stimulated with LPS. This observation is consistent with the
model that has been proposed for HCV infection (56), in
which exogenous IFN can drive the evolution of strains resis-
tant to IFN-mediated antiviral activity.
Alphaviruses efficiently induce IFN-a/b and are also gener-
ally highly sensitive to the antiviral effects of IFN-a/b (3, 46,
62). For instance, based on human and mouse studies, low
levels of IFN-b can efficiently inhibit chikungunya virus
(CHIKV) infection (46). Mice deficient in the IFN-a/b recep-
tor (IFN-a/bR2/2) are highly susceptible to CHIKV infection,
with infection resulting in death within 3 days (8). Similarly,
RRV infection resulted in substantial mortality in IFN-a re-
ceptor-deficient mice (IFN-a R2/2), while wild-type mice were
able to resist infection (J. Podger and S. Mahalingam, unpub-
lished data). In terms of induction and sensitivity to IFN, our
results show that RRVPERS induces less IFN-b and exhibits
resistance to its antiviral effects compared to the parent virus.
Mortality and disease severity were greatly enhanced in mice
infected with RRVPERS compared to those infected with
RRV-T48. The reduction in IFN-b production observed in
vitro following infection with RRVPERS was also observed in
vivo, with a 50% reduction in IFN-b levels in the lymph nodes
of mice infected with RRVPERS compared to results for those
infected with RRV-T48. It is likely that the virus-mediated
FIG. 5. RRVPERS infection in mice results in enhanced mortality associated with reduced IFN-b expression. (A to C) Survival of 14-day-old Swiss
outbred mice after intraperitoneal (i.p.) infection with RRV-T48 (open circles) or RRVPERS (closed circles). Virus was inoculated at doses ranging from
104 (A) or 105 (B) to 106 (C) PFU/mouse (n5 10). Differences between survival curves were calculated using the log rank test. P, 0.05 was considered
to be significant. (D) Titers of RRV-T48 and RRVPERS (log10 PFU/ml) in the serum of 14-day-old Swiss outbred mice infected subcutaneously (s.c.) 24 h
previously with 104 PFU/mouse. The plaque assay limit of detection is 2.0 log10 PFU/ml. Significant differences in virus titers (P, 0.05) are marked with
an asterisk. (E) IFN-b concentration in homogenized lymph nodes of 5-week-old Swiss outbred mice 24 h after s.c. infection with 104 PFU RRV-T48
or RRVPERS (n 5 3 mice per group). Significant differences in protein levels (P , 0.05) are marked with an asterisk.
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inhibition of the type I IFN response contributes to disease
exacerbation following infection with RRVPERS. Our results
are reminiscent of findings with Venezuelan equine encepha-
litis virus (VEEV), in which infection of mice with an IFN-
resistant strain resulted in enhanced clinical disease (51). Sim-
ilar results were obtained with an IFN-a/b-resistant eastern
equine encephalitis virus (EEEV) strain; infection of mice with
this strain resulted in enhanced encephalitis, an effect that
mapped to both structural and nonstructural genes (1).
To counteract type I IFN responses, many viruses encode
proteins that disrupt type I IFN signaling and downstream
responses. These evasion strategies have been linked to viral
FIG. 6. RRVPERS induced severe RRVD in a mouse model of disease. Eighteen-day-old outbred mice were infected with 10
4 PFU of RRV-T48
or RRVPERS by injection in the left rear footpad. (A) Mice were scored for development of hind limb dysfunction and disease based on the
following scale: 0, no disease; 1, ruffled fur; 2, very mild hind limb weakness; 3, mild hind limb weakness; 4, moderate hind limb weakness; 5, severe
hind limb weakness/dragging; 6, complete loss of hind limb function; 7, moribund; 8, dead (n 5 5). Data for disease scores were analyzed by the
Mann-Whitney test. Significant differences in disease score (P , 0.05) are indicated with an asterisk. (B) Eighteen-day-old outbred mice were
infected with 104 PFU of RRV by injection in the left rear footpad. At 5 days p.i., mice were perfused with 4% paraformaldehyde, and 5-mm-thick
paraffin-embedded sections generated from quadriceps muscle were hematoxylin and eosin (H&E) stained; (a) Mock; (b) RRV-T48-infected mice;
(c) RRVPERS-infected mice. Images are representative of at least 3 mice per group. Magnifications: a, c, and e, 3100; b, d, and f, 3200.
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pathogenesis and the emergence of virus in new host popula-
tions (24, 51). Suppression of type I IFN responses has been
observed for influenza virus (4, 14), dengue virus (20, 39), West
Nile virus (32) and other RNA viruses (reviewed in references
15 and 35). Many viral proteins have been reported to block
transcription factors that control production of type I IFN
(reviewed in references 14, 15, and 35). In this study we have
identified RRV as an additional member capable of develop-
ing mechanisms to suppress IFN responses. Alphavirus infec-
tion results in rapid shutdown of host cell protein synthesis in
favor of viral protein synthesis, and the conventional view has
been that this mechanism underlies the observed suppression
of IFN-a/b production (44). For example, the nsP2 proteins of
Sindbis virus and Semliki Forest virus (SFV) can inhibit type I
IFN responses via host protein shutdown (5, 12), while the
capsid proteins of EEEV and VEEV perform a similar IFN-
targeting function (1, 2, 51). Mutating the nuclear localization
sequence of nsP2 of SFV resulted in a virus that induced more
IFN-a/b, suggesting that nsP2 inhibits IFN-a/b induction (5).
However, those authors admit that an alternative explanation
is that relocalization of nsP2 may simply result in more-effec-
tive induction of IFN-a/b (5). Alphaviruses might also exert
much more specific effects on the IFN-a/b system independent
of host protein shutoff. Our earlier studies with RRV demon-
strated that Fc receptor bearing cells (dendritic cells [DCs] and
macrophages) can be infected via a mechanism involving an-
tibody-dependent enhancement (ADE) of infection and that
this results in interleukin 10 (IL-10)-dependent inhibition of
cellular IFN-a/b production (34). We have also demonstrated
that the presence of high-mannose glycans on virus derived
from mosquito cells interferes with type I IFN induction in
myeloid DCs (47). Recently, Yin and colleagues reported that
the phosphorylation of STAT-1 and STAT-2 was partially
blocked by VEEV and Sindbis virus and the effect was depen-
dent on the expression of viral nsP (61). In another study,
Simmons et al. showed that VEEV can antagonize STAT-1
activation following type I IFN treatment and that the inhibi-
tion of type I IFN signaling occurred via distinct mechanisms
independent of host protein shutoff (49). Cruz et al. have
identified a mutation in the nsP1/nsP2 cleavage domains of
Sindbis virus and RRV associated with a specific enhancement
of IFN production independent of virus-induced host shutoff
(9). More recently, Fros et al. showed that chikungunya virus
infection blocked IFN-induced STAT-1 phosphorylation and
that this inhibition was mediated by nsP2 and was independent
of host shutoff (13). Several lines of evidence also suggest that
shutdown of host protein synthesis is not responsible for the
RRVPERS-mediated IFN-a/b signaling inhibition. First, the
reduced levels of phosphorylated STAT-1 were not associated
with reduced total STAT-1 levels, which suggests that the in-
hibition was not due to decreased synthesis of total STAT-1.
Second, phosphorylated STAT-2, total STAT-2, and house-
keeping gene a-actin levels were not decreased by RRVPERS
infection, which indicates that the small-plaque variant specif-
ically targets STAT-1. Third, the STAT-1 and STAT-2 levels in
uninfected controls treated with IFN were comparable to lev-
els in cells infected with RRV-T48 and treated with IFN,
suggesting that RRV-T48 does not inhibit phosphorylation of
STAT-1 or -2 and that the effects are specific to RRVPERS.
The ability of viruses to develop resistance to host antiviral
activity by genetic sequence variation has a major effect on
virus virulence and persistence in the host. Mutational studies
have shown that alphaviruses appear to attain these effects
mainly through the action of nsPs (1, 2, 5, 9, 13, 51). We
identified a number of mutations in nsP1 to nsP4 and a single
mutation in E2 in RRVPERS. Using site-directed mutagenesis,
we introduced the RRVPERS E2 mutation into the parent
RRV-T48 cDNA infectious clone (adenine to uracil
[GAG3GUG] at position E2-347). Interestingly, the mutation
in E2 did not affect IFN induction and resistance of RRVPERS
(data not shown). Future studies will investigate whether these
mutations in the nsP regions are involved in the perturbation
of IFN signaling pathways that we observed. Our preliminary
studies (using chimeric virus and a pcDNA plasmid expressing
nonstructural genes) show that RRVPERS nsP1 and nsP2 are
able to inhibit IFN-a/b signaling (data not shown), and we are
currently attempting to identify the mechanisms of action. Fu-
ture studies will introduce the mutations that we identified in
the RRVPERS nsPs into the wild-type RRV infectious clone
(pRR64), followed by testing of the IFN resistance phenotype
and pathogenicity of the recombinant virus. If the IFN resis-
tance phenotype of RRVPERS is recovered, examination of the
expression of downstream IFN-induced proteins will be inves-
tigated. These studies will allow us to identify the specific nsP
mutation(s) that leads to the IFN suppression phenotype in-
duced by enhanced macrophage inflammatory activity.
In conclusion, we describe in vitro and in vivo studies char-
acterizing the genetic and phenotypic properties of a novel
small-plaque, persistent strain of RRV. The enhanced suppres-
sion of IFN signaling mediated by RRVPERS is likely to play a
key role in the enhanced pathogenicity exhibited by this virus.
This study demonstrates that selective pressure exerted by host
antiviral activity can promote the evolution of an IFN-resis-
tant, persistent, and highly pathogenic alphavirus strain. It is
possible that a similar evolutionary mechanism may operate in
vivo, and sequencing of clinical isolates from persistent alpha-
virus infections will provide new insights into viral pathogene-
sis in human disease.
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